<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39388034</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-2027</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>PharmacoEconomics</Title><ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation></Journal><ArticleTitle>The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40273-024-01436-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We conducted a distributional cost-effectiveness analysis to evaluate how coverage of tocilizumab for inpatients with COVID-19 from 2021 to present impacted health equity in the USA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A published, payer-perspective, distributional cost-effectiveness analysis for inpatient COVID-19 treatments was adapted to include information on baseline health disparities across 25 equity-relevant subgroups based on race and ethnicity (5 census-based groups), and county-level social vulnerability (5 geographic quintiles). The underlying cost-effectiveness analysis was updated to reflect patient characteristics at admission, standard of care outcomes, tocilizumab efficacy, and contemporary unit costs. The distributional cost-effectiveness analysis inputs for COVID-19 hospitalization and subgroup risk adjustments based on social vulnerability were derived from published estimates. Opportunity costs were estimated by converting total tocilizumab spend into quality-adjusted life-years (QALYs), distributed equally across subgroups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tocilizumab treatment was cost effective across all subgroups. Treatment resulted in larger relative QALY gains in more socially vulnerable subgroups than less socially vulnerable subgroups, given higher hospitalization rates and inpatient mortality. Using an opportunity cost threshold of US$150,000/QALY and an Atkinson index of 11, tocilizumab was estimated to have improved social welfare by increasing population health (53,252 QALYs gained) and reducing existing overall US health inequalities by 0.003% since 2021.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of tocilizumab for COVID-19 since 2021 increased population health while improving health equity, as more patients with lower baseline health were eligible for treatment and received larger relative health gains. Future equitable access to tocilizumab for inpatients with COVID-19 is expected to lead to continued increases in population health and reductions in disparities.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kowal</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. kowal.stacey@gene.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosettie</LastName><ForeName>Katherine L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Pharmacoeconomics</MedlineTA><NlmUniqueID>9212404</NlmUniqueID><ISSNLinking>1170-7690</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39388034</ArticleId><ArticleId IdType="doi">10.1007/s40273-024-01436-1</ArticleId><ArticleId IdType="pii">10.1007/s40273-024-01436-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention (CDC). COVID data tracker. 2024. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home . [Accessed 24 Feb 2024].</Citation></Reference><Reference><Citation>Lopez L, Hart LH, Katz MH. Racial and ethnic health disparities related to COVID-19. JAMA. 2021;325:719–20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26443</ArticleId><ArticleId IdType="pubmed">33480972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipirneni R, Schmidt H, Lantz PM, Karmakar M. Associations of 4 geographic social vulnerability indices with US COVID-19 incidence and mortality. Am J Public Health. 2022;112(11):1584–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2022.307018</ArticleId><ArticleId IdType="pubmed">36108250</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JT, Luna-Pinto C, Cox H, Razi S, St Louis ME, Ricaldi JN, et al. Promoting health equity during the COVID-19 pandemic, United States. Bull World Health Organ. 2022;100(2):171–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.21.286074</ArticleId><ArticleId IdType="pubmed">35125543</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Weintraub R, Williams MA, Miller K, Buttenheim A, Sadecki E, et al. Equitable allocation of COVID-19 vaccines in the United States. Nat Med. 2021;27:1298–307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01379-6</ArticleId><ArticleId IdType="pubmed">34007071</ArticleId></ArticleIdList></Reference><Reference><Citation>Agboola F, Whittington MD, Pearson SD. Institute for Clinical and Economic Review (ICER). Advancing health technology assessment methods that support health equity. 2023. Available from: https://icer.org/wp-content/uploads/2022/07/ICER_Advancing-Health-Technology-Assessment-Methods-that-Support-Health-Equity_040523.pdf . [Accessed 14 Apr 2023].</Citation></Reference><Reference><Citation>Benkhalti M, Espinoza M, Cookson R, Welch V, Tugwell P, Dagenais P. Development of a checklist to guide equity considerations in health technology assessment. Int J Technol Assess Health Care. 2021;37: e17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462320002275</ArticleId><ArticleId IdType="pubmed">33491618</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslau RM, Cohen JT, Diaz J, Malcolm B, Neumann PJ. A review of HTA guidelines on societal and novel value elements. Int J Technol Assess Health Care. 2023;39(1): e31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S026646232300017X</ArticleId><ArticleId IdType="pubmed">37226807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal S, Ng CD, Schuldt R, Sheinson D, Cookson R. The impact of funding inpatient treatments for COVID-19 on health equity in the United States: a distributional cost-effectiveness analysis. Value Health. 2023;26:216–25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2022.08.010</ArticleId><ArticleId IdType="pubmed">36192293</ArticleId></ArticleIdList></Reference><Reference><Citation>Innovation and Value Initiative (IVI): health equity initiative. No value without equity: transforming practice and accountability for equity in health technology assessment. 2023. Available from: https://thevalueinitiative.org/wp-content/uploads/2023/03/No-Value-Without-Equity_Synthesis-Insight.pdf . [Accessed 18 Jun 2023].</Citation></Reference><Reference><Citation>Kowal S, Ng CD, Schuldt R, Sheinson D, Jinnett K, Basu A. Estimating the US baseline distribution of health inequalities across race, ethnicity, and geography for equity-informative cost-effectiveness analysis. Value Health. 2023;26:1485–93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2023.06.015</ArticleId><ArticleId IdType="pubmed">37414278</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration (US FDA). Fact sheet for healthcare providers: emergency use authorization for Actemra<sup>®</sup>. 2021. Available from: https://www.fda.gov/media/150321/download#:~:text=EMERGENCY%20USE%20AUTHORIZATION-,The%20U.S.%20Food%20and%20Drug%20Administration%20(FDA)%20has%20issued%20an,receiving%20systemic%20corticosteroids%20and%20require . [Accessed 14 Mar 2023].</Citation></Reference><Reference><Citation>Isath A, Malik AH, Goel A, Gupta R, Shrivastav R, Bandyopadhyay D. Nationwide analysis of the outcomes and mortality of hospitalized COVID-19 patients. Curr Probl Cardiol. 2023;48: 101440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2022.101440</ArticleId><ArticleId IdType="pubmed">36216202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01654-5</ArticleId><ArticleId IdType="pubmed">33650025</ArticleId></ArticleIdList></Reference><Reference><Citation>Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.10.008</ArticleId><ArticleId IdType="pubmed">35031088</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO-REACT Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499–518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11330</ArticleId></ArticleIdList></Reference><Reference><Citation>AnalySource<sup>®</sup>. Database. https://www.analysource.com/ . Accessed May 2023.</Citation></Reference><Reference><Citation>Healthcare Cost and Utilization Project (HCUP). National inpatient sample. 2020. Available from: https://hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2020.jsp . [Accessed 19 Mar 2024].</Citation></Reference><Reference><Citation>Centers for Medicare and Medicaid Services (CMS). CMS FY 2023 IPPS final rule. 2023. Available from: https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2023-ipps-final-rule-home-page . [Accessed 15 Mar 2024].</Citation></Reference><Reference><Citation>Genentech Inc. Highlights of prescribing information: Actemra<sup>®</sup> (tocilizumab) injection, for intravenous or subcutaneous use. 2022. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf . [Accessed 15 Mar 2024].</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Intubation or ventilator use in the hospital by week from selected hospitals. 2023. Available from: https://www.cdc.gov/nchs/covid19/nhcs/intubation-ventilator-use.htm . [Accessed 15 Mar 2023].</Citation></Reference><Reference><Citation>US Bureau of Labor Statistics. (BLS). US Bureau of Labor Statistics. Measuring price change in the CPI: medical care. 2024. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm . [Accessed 25 Apr 2024].</Citation></Reference><Reference><Citation>Cookson R, Griffin S, Norheim OF, Culyer AJ, Chalkidou K. Distributional cost-effectiveness analysis comes of age. Value Health. 2021;24:118–20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2020.10.001</ArticleId><ArticleId IdType="pubmed">33431145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson R, Griffin S, Norheim OF, Culyer AJ. Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs. Oxford: Oxford University Press; 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/med/9780198838197.001.0001</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Toxic Substances and Disease Registry (ATSDR). At a glance: CDC/ATSDR social vulnerability index. 2021. Available from: https://www.atsdr.cdc.gov/placeandhealth/svi/at-a-glance_svi.html . [Accessed 15 Mar 2024].</Citation></Reference><Reference><Citation>Remington PL, Catlin BB, Gennuso KP. The County Health Rankings: rationale and methods. Popul Health Metr. 2015;13:11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12963-015-0044-2</ArticleId><ArticleId IdType="pubmed">25931988</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Site to download COVID hospitalization data. 2013. Available from: https://covid.cdc.gov/covid-data-tracker/#trends_weeklyhospitaladmissions_select_00 . [Accessed 15 Mar 2024].</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). COVID-NET. 2023. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covidnetdashboard/de/powerbi/dashboard.html . [Accessed 15 Mar 2024].</Citation></Reference><Reference><Citation>Nayak A, Islam SJ, Mehta A, Ko YA, Patel SA, Goyal A, et al. Impact of social vulnerability on COVID-19 incidence and outcomes in the United States. medRxiv. 2020;80(1):34.</Citation></Reference><Reference><Citation>Karmakar M, Lantz PM, Tipirneni R. Association of social and demographic factors with COVID-19 incidence and death rates in the US. JAMA Netw Open. 2021;4(1): e2036462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36462</ArticleId><ArticleId IdType="pubmed">33512520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Bowen VB, Leidner A, Fletcher K, Musial T, Rose C, et al. Association between social vulnerability and a county’s risk for becoming a COVID-19 hotspot: United States, June 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(42):1535–41.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6942a3</ArticleId><ArticleId IdType="pubmed">33090977</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CA, Patel K, Patton ME, Reingold A, Kawasaki B, Meek J, et al. COVID-19-associated hospitalizations among U.S. adults aged ≥ 65 Years: COVID-NET, 13 States, January-August 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1089–94.</Citation></Reference><Reference><Citation>Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990–2021. JAMA. 2023;329(15):1312–4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.1792</ArticleId><ArticleId IdType="pubmed">37071104</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson M, Asaria M, Cookson R, Tsuchiya A, Ali S. Eliciting the level of health iequality aersion in England. Health Econ. 2017;26(10):1328–34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3430</ArticleId><ArticleId IdType="pubmed">27649686</ArticleId></ArticleIdList></Reference><Reference><Citation>Meunier A, Longworth L, Gomes M, Ramagopalan S, Garrison LP, Popat S. Distributional cost-effectiveness analysis of treatments for non-small cell lung cancer: an illustration of an aggregate analysis and its key drivers. Pharmacoeconomics. 2023;41(8):1011–25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-023-01281-8</ArticleId><ArticleId IdType="pubmed">37296369</ArticleId></ArticleIdList></Reference><Reference><Citation>Meunier A, Longworth L, Kowal S, Ramagopalan S, Love-Koh J, Griffin S. Distributional cost-effectiveness analysis of health technologies: data requirements and challenges. Value Health. 2023;26(1):60–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2022.06.011</ArticleId><ArticleId IdType="pubmed">35941004</ArticleId></ArticleIdList></Reference><Reference><Citation>Love-Koh J, Asaria M, Cookson R, Griffin S. The social distribution of health: estimating quality-adjusted life expectancy in England. Value Health. 2015;18(5):655–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2015.03.1784</ArticleId><ArticleId IdType="pubmed">26297094</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Calhoun C, Ito S, James LP, Luviano A, Krishnamurti L, et al. Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States. Ann Intern Med. 2023;176(6):779–87.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-3272</ArticleId><ArticleId IdType="pubmed">37247420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafrin J, Kim J, Marin M, Ramsagar S, Davies ML, Stewart K, et al. Quantifying the value of reduced health disparities: low-dose computed tomography lung cancer screening of high-risk individuals within the United States. Value Health. 2024;27(3):313–21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2023.12.014</ArticleId><ArticleId IdType="pubmed">38191024</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer: a distributional cost-effectiveness analysis. Value Health. 2023;26:1697–710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2023.08.010</ArticleId><ArticleId IdType="pubmed">37741446</ArticleId></ArticleIdList></Reference><Reference><Citation>Slejko JF, Ricci S, dosReis S, Kowal S. Eliciting inequality aversion in the United States: results from a benefit trade-off experiment. Value Health. 2024;27:S208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2024.03.1147</ArticleId></ArticleIdList></Reference><Reference><Citation>McQueen RB, Inotai A, Zemplenyi A, Mendola N, Nemeth B, Kalo Z. Multistakeholder perceptions of additional value elements for United States value assessment of health interventions. Value Health. 2024;27:15–25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2023.09.2910</ArticleId><ArticleId IdType="pubmed">37820753</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19: final report. N Engl J Med. 2020;383(19):1813–26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410–20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X06290495</ArticleId><ArticleId IdType="pubmed">16855129</ArticleId></ArticleIdList></Reference><Reference><Citation>Padula WV, Malaviya S, Reid NM, Cohen BG, Chingcuanco F, Ballreich J, et al. Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. J Med Econ. 2021;24(1):1060–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2021.1965732</ArticleId><ArticleId IdType="pubmed">34357843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11(7):1131–43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2008.00352.x</ArticleId><ArticleId IdType="pubmed">18489495</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011802</ArticleId><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>